/

Empresas

Da

No verificado

Daiichi Sankyo

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

98 Comunicados de prensa

Ver todos los comunicados de prensa

31/07/2026

Web y redes sociales

Telefonía

Mercado de valores

Ciencia

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Oncología

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fuente

Editor

1.00

0

31/07/2026

Mercado laboral

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Fuente

Editor

1.00

0

24/07/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Fuente

Editor

1.00

0

29/06/2026

Oncología

Salud

Biotecnología

Sanidad

Medicina - Varios

Farmacéutica

Industria

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Fuente

Editor

1.00

0

26/06/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Fuente

Editor

1.00

0

28/05/2026

Eventos

Industria

Ciencia

Biotecnología

Medicina - Varios

Salud

Farmacéutica

Sanidad

Oncología

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO

Fuente

Editor

1.00

0

22/05/2026

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Higiene alimentaria

Medicina - Varios

Industria

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Fuente

Editor

1.00

0

22/05/2026

Oncología

Salud

Biotecnología

Medicina - Varios

Farmacéutica

Mercado laboral

Industria

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Fuente

Editor

1.00

0

15/05/2026

Industria

Oncología

Salud

Higiene alimentaria

Medicina - Varios

Farmacéutica

Biotecnología

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

11/05/2026

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0